Furthermore, Muralimanoharan described a downregulation of pAMPK in placenta from pharmacologically treated GDM patients, that could be responsible for mTOR pathway activation and could be involved in the shift toward aerobic glycolysis observed in GDM [67]. This evidence concerns the gene MTOR and gestational diabetes.